RPG Life Sciences on Friday reported a 15% increase in operating revenue at Rs 148 crore for the June quarter of the current fiscal year against the Rs 129 crore reported in the year-ago quarter.

RPG Life Science is a Pharmaceutical firm that is engaged in the business of manufacturing and marketing pharmaceutical products.

According to the Managing Director of the company Mr Yugal Sikri, the firm’s performance continues to be strong, despite the ongoing geo-political challenges impacting the supply chain and costs.

He said the domestic formulations business, the most significant contributor to the company’s business, has recorded a robust growth in volume and value that is significantly and consistently ahead of the market.

EBITDA increased by 17% to Rs 34 crore for the first quarter of FY24 against the Rs 29.1 crore posted in Q1FY23.

The company’s EBITDA margins have increased by 50 basis points to 23% for Q1Fy24.

Sikri added, “The company is investing in plant modernisation and capacity expansion in both plants as well as working on building a healthy product pipeline to accelerate exports,”

The company has various therapeutic areas that offer a range of formulations and active pharmaceutical ingredients (APIs).

Shares of RPG Life Science reached a new 52-week high of Rs 1,128.50 on July 31 on NSE.

At 3:00 pm, the share traded at Rs 1,073.85 or 3.31% above its previous close.